Product Data SheetProduct Name:CAS No.: Cat. No.:MWt:Formula:Purity :Avanafil330784-47-9HY-18252483.95C23H26ClN7O3>98%Solubility:DMSOMechanisms: Pathways:Others; Target:PDE Biological Activity:Avanafil(TA1790) is a potent and highly selective phosphodiesterase5(PDE5) inhibitor(IC50=5.2Avanafil(TA-1790)isapotentandhighlyselectivephosphodiesterase-5(PDE-5)inhibitor(IC50=52nM) for erectile dysfunction; lower selectivity against PDE1, PDE6, and PDE11. IC50 value: 5.2 nM [1] Target: PDE5 Avanafil is highly selective toward PDE5 and against all other PDE isozymes tested. Lowerselectivity against PDE1, PDE6, and PDE11 is consistent with results from randomized, placebo-controlled, phase 3 trials in which musculoskeletal and hemodynamic adverse events were reportedin <2% of patients and no color vision-related abnormalities were reported with avanafil doses up to200mg once daily [2]. Intraduodenal doses of avanafil or sildenafil (0.1 and 1 mg/kg) potentiated theAUC of nitroglycerin induced hypotension. However, the potentiating effect of avanafil at 1 mg/kgwas significantly weaker than that of sildenafil (p <0.05) [3]....References:[1]. Kotera J, et al. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectiledysfunction. J Urol. 2012 Aug;188(2):668-74. [2]. Wang R, et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction:implications for clinical safety and improved tolerability. J Sex Med. 2012 Aug;9(8):2122-9. [3]. Mochida H, et al. Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectiledysfunction, shows good safety profiles for retinal function and hemodynamics in anesthetized dogs.J Urol. 2013 Aug;190(2):799-806. Caution: Not fully tested. For research purposes onlyMedchemexpress LLCwww.medchemexpress.com 18 Wilkinson Way, Princeton, NJ 08540,USAess.com Web: www.medchemexpress.comEmail: info@medchemexpr
